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1. Introduction
1.1. Capsaicin-sensitive afferent nerves
Capsaicin-sensitive afferent nerves play an important role in maintaining the integrity of the
gastric mucosa. Stimulation of these nerves by capsaicin has been demonstrated to protect
gastric mucosa from a variety of noxious stimuli through increased gastric mucosal blood flow
(GMBF) [1, 2]. The binding site of capsaicin has been cloned, and named transient receptor
potential vanilloid type 1 (TRPV1), a nonselective cation channel [3]. It is reported that
capsaicin stimulates these afferent nerves through activation of TRPV1, resulting in gastric
mucosal protection [4] and gastric hyperemic response [5], which are mediated by both
calcitonin gene-related peptide (CGRP) and nitric oxide (NO) [6, 7]. Indeed, it has been shown
that gastric mucosal vasodilation induced by intragastric application of capsaicin was reduced
by the inhibitor of NO synthase (NOS), NG-nitro-L-arginine methyl ester (L-NAME) [8].
1.2. Nitric oxide synthase
NO has been reported to affect gastric mucosal blood flow [9]. In mammals, three isoforms of
NOS encoded by different genes have been identified [10]. The constitutively expressed
isoforms include neuronal NOS (nNOS) present in the neuron and endothelial NOS (eNOS)
present in the endothelium lining the vasculature. Inducible NOS (iNOS) requires a stimulus
(cytokines and lipopolysaccharides) for expression in specific cell types such as macrophages,
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neutrophils, and epithelial cells. Therefore, eNOS-derived NO is assumed to contribute to the
gastric hyperemic response to capsaicin although the gastric mucosa has been shown to contain
not only eNOS [11, 12] but also nNOS [11] and iNOS [13].
Interestingly, Chen et al. [14] speculated that NO comes from not only endothelium but also
nitroxidergic nerves in the submucosa in gastric vasodilation response to capsaicin. However,
it has not been studied which NOS isoforms contribute to gastric hyperemic responses to
capsaicin thus far.
1.3. Aim
In the present report, we examined to determine the roles of NOS isoforms on gastric hypere‐
mic response to capsaicin in urethane-anesthetized rats by using pharmacological tools,
including N5-[imino (propylamino) methyl]-L-ornithine, (NPLA; a selective nNOS inhibitor),
N5-(l-iminoethyl)-L-ornithine (L-NIO; a selective eNOS inhibitor), and 1400W (a selective iNOS
inhibitor). In addition, we investigated the localization relationship of nNOS and TRPV1-
expressing nerves in rat stomachs by using immunohistochemical analysis.
2. Material and methods
2.1. Animals
Male Sprague–Dawley strain rats (SLC, Hamamatsu, Japan) weighing 180–220 g were used.
Animals were housed under controlled environmental conditions (temperature, 24 ± 2°C and
lights on 7:00 am to 7:00 pm) and fed commercial rat chow MF (Oriental Yeast, Tokyo, Japan).
The animals were kept in individual cages with raised mesh bottoms to prevent coprophagy,
and they were deprived of food but allowed free access to tap water for 18 h before the
experiments. Animal experiments were performed according to the “Guiding Principles for
the Care and Use of Laboratory Animals” approved by the Japanese Pharmacological Society
and the guidelines approved by the Ethical Committee on Animal Care and Animal Experi‐
mentation of Josai International University (#52). The number of animals used was kept to the
minimum necessary for meaningful interpretation of the data.
2.2. Preparations and drugs used
Atenolol, capsaicin, CMC, dimethyl sulfoxide (DMSO), dl-isoproterenol, and urethane (ethyl
carbamate) were obtained from Wako Pure Chemical Industries (Osaka, Japan). L-arginine, L-
NAME, and omeprazole were from Sigma-Aldrich (St. Louis, MO, USA). NPLA and L-NIO
came from Tocris Cookson (Ellisville, MO, USA). N-(4-t-Butylphenyl)-4-(3-chlopyridin-2-yl)
tetrahydropyrazine-1(2H)-carboxamide (BCTC) was purchased from BIOMOL (Plymouth
Meeting, PA, USA). Capsaicin was dissolved in Tween 80-ethanol solution (10% ethanol, 10%
Tween 80, and 80% saline) for s.c. injection or suspended in 0.5% CMC for mucosal application.
Omeprazole was suspended in 0.5% CMC for i.p. injection. BCTC was dissolved in DMSO
prior to dilution in saline, and the final concentration of DMSO was less than 1.0%. Other drugs
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were dissolved in saline with no organic solvent or detergent. Each drug was prepared
immediately before use and was given in a volume of 0.5 ml/100 g of body wt. in the case of
i.p. and s.c. administration or in a volume of 0.1 ml/100 g of body wt. in case of i.v. adminis‐
tration. Control animals received the vehicle alone.
2.3. Gastric mucosal blood flow
The measurement of gastric blood flow was carried out as described previously [15]. The
animals were anesthetized with urethane (1.25 g/kg, i.p.). The stomach was exposed through
a midline incision, delivered onto the abdominal surface by gentle traction on the spleen, and
pylorus was ligated. The lucite chamber was used for maintaining ex vivo conditions of gastric
mucosa. The lucite chamber, known as the ex vivo chamber, consists of two parts: one part is
a lucite base and the other is plastic rim which has two holes on the side wall. Two holes are
cannulated for perfusing the mucosa with saline (154 mmol/l NaCl, 37°C) at a flow rate of 1
ml/min. The lucite base was lowered over the animals, and the stomach was drawn though
the center hole with the forceps applied only to the forestomach. The stomach was then opened
along the greater curvature from the middle part of the forestomach to the area where the
epiploic artery is terminated, and the edges were pinned out by gently stretching the glandular
mucosa. The plastic rim was then applied and tightened down on the mucosa. Under these
conditions, the exposed area was exclusively the glandular mucosa, mostly consisting of
corpus region. The chamber was set at the level of the abdominal wall so that the external wall
of the stomach remained inside the abdominal cavity. The body temperature was maintained
at a temperature similar to that of the rectum at around 37°C by using a small animal warmer
and thermometer (Bio Research Center, Model BWT-100, Nagoya, Japan). Gastric mucosal
blood flow was measured by laser-Doppler flowmetry (Advance, Model ALF-21N, Tokyo,
Japan) and by a non-touching probe (1 mm in diameter) on the surface of the corpus mucosa.
After gastric mucosal blood flow was well stabilized, the perfusion was discontinued, the
luminal solution was removed, and then the mucosa was exposed to 2 ml of capsaicin for 10
min. After application, the mucosa was rinsed with saline, another 2 ml of saline was instilled,
and the perfusion resumed. Changes in the gastric mucosal blood flow were continuously
monitored and recorded for 2-h test periods by using the PowerLab system (Model ML845;
AD Instruments, Bella Vista, NSW, Australia).
2.4. Experimental procedures
A TRPV1 antagonist N-(4-t-butylphenyl)-4-(3-chlopyridin-2-yl) tetrahydropyrazine-1(2H)-
carboxamide (BCTC) (0.8 mmol/L, i.g.) [16], a non-selective NOS inhibitor NG-nitro-L-arginine
methyl ester (L-NAME; 5 and 10 mg/kg, i.v.), a nNOS selective inhibitor NPLA (0.02 and 0.2
mg/kg, i.v.), an eNOS selective inhibitor L-NIO (3 and 10 mg/kg, i.v.), and an iNOS selective
inhibitor 1400W (3 and 10 mg/kg, i.v.) were administered 20 min before exposing the stomach
to 2 ml of capsaicin for 10 min. In one group, L-arginine (300 mg/kg, i.v.) was administered
twice 40 min and 60 min before the application of capsaicin.
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2.5. Chemical deafferentation
Chemical deafferentation was performed two weeks before the experiment by successive
injections of capsaicin subcutaneously once daily for 3 d (20, 30, and 50 mg/kg) [17]. All
capsaicin injections were performed under ether anesthesia, and the rats were pretreated with
the beta-adrenergic receptor agonist isoproterenol (0.01 mg/kg, i.m.) and the selective beta 1-
adrenergic antagonist atenolol (0.01 mg/kg, i.m.) to counteract the respiratory impairment
associated with capsaicin injection. To check for the effectiveness of the treatment, a drop of a
0.1 mg/ml solution of capsaicin in 0.5% carboxymethyl cellulose solution (CMC) was instilled
into one eye of each rat, and the protective wiping movements were counted [18].
2.6. Immunohistochemical study
The immunohistochemical procedures were performed as described previously [4]. The
corpora of rat stomachs were fixed by immersion in fresh 4% paraformaldehyde in 0.1 mol/l
phosphate buffer (pH 7.4) for 2 h at 4°C, and washed three times with phosphate-buffered
saline (PBS). They were cryoprotected overnight in 0.1 mol/l phosphate buffer containing 20%
sucrose. The tissues were frozen in OCT mounting medium (Sakura Finetek Europe, Zoeter‐
woude, The Netherlands), and sectioned on a cryostat (Leica, Hemel Hempstead, UK) at a
thickness of 60 μm. The tissue sections were thaw-mounted onto Superfrost Plus slides (BDH
Laboratory Supplies, Poole, UK). Prior to staining, the slide-mounted sections were incubated
in PBS containing 0.3% hydrogen peroxide for 30 min to quench endogenous peroxidase
activity and washed with PBS. The sections were successively incubated in 10% normal donkey
serum containing 0.2% Triton X-100, 0.1% sodium azide in PBS for 1 h, and polyclonal anti-
TRPV1 antibody (1:15000) for 40 h at room temperature. TRPV1 immunoreactivity was
detected using a polyclonal antiserum raised in rabbit against the carboxy terminus of rat
TRPV1 provided by Dr. David Julius. After washes in PBS, the sections were incubated with
biotinylated donkey anti-rabbit immounoglobulin G (1:400; Jackson Immunoresearch Labo‐
ratories, West Grove, PA, USA) for 90 min at room temperature. After further washes, the
sections were incubated in stretavidin biotin-peroxidase complex (1:5 in PBS; Vectastain Elite
ABC kit, Vector Laboratories, Peterborough, UK) for 1 h at room temperature followed by
fluorescein tyramide (1:75; TSA kit, PerkinElmer Life Sciences, Boston, MA, USA). In control
experiments, the TRPV1 antibody was omitted from the staining procedures to verify the
specificity of the staining. No immunolabeling was observed in these controls.
Double staining of the section with TRPV1 antiserum combined with protein gene product 9.5
(PGP 9.5) and nNOS antisera was also performed. TRPV1 staining was carried out first using
the TSA procedure with FITC, following by PGP 9.5 or nNOS staining using indirect labeling
procedure as described below. The sections were incubated for 40 h at room temperature in
the PGP 9.5 or nNOS primary antibody solution, and then washed three times for 10 min each
in PBS. To visualize the labeling, sections were then incubated for 4 h with the corresponding
secondary antibody linked to tetramethyl rhodamine isothiocyanate (TRITC, 1:400; Jackson
Immunoresearch Laboratories). Antisera were diluted in PBS containing 0.2% Triton X-100
and 0.1% sodium azide. Two sets of controls were processed for this double labeling. First, the
primary antibodies in the first and second stainings were omitted from the staining procedures.
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No immunolabeling was observed in this control. Second, only the primary antibody in the
second staining was omitted from the staining procedures. In this control, FITC labeling of
TRPV1 fibers was seen, but TRITC labeling was not.
2.7. Microscopy
Sections were viewed on either a Leica epifluorescence microscope using Y3 (TRITC) and L4
(FITC) filter blocks, or on a upright Zeiss confocal laser scanning microscope system (LSM510)
and ×20, ×40 Plan Neofluar objectives. On the latter system, single tracking mode was used for
single FITC labeling. Sections were scanned in multitracking mode (to avoid channel cross
talk) when double labeling was done with FITC (488 nm) and TRITC (543 nm). Each image
was produced by projecting all the slices of the stack onto one plane. Final plates were prepared
using Adobe Photoshop.
2.8. Statistics
The data are presented as the means ± S.E.M. from 3–7 rats per group. The statistical signifi‐
cance of differences between two groups was assessed using Student’s t-test. Multiple
comparisons against a single control group were made by a one-way analysis of variance
ANOVA with Bonferroni correction. The level of significance was set at 0.05. Sigma Stat 3.1
software (Jandel Scientific Software, San Rafael, CA, USA) procedure was applied for statistical
analysis.
3. Results
3.1. Effects of intragastric capsaicin on gastric mucosal blood flow
Intragastric capsaicin (0.33, 1, and 3.3 mmol/l) induced gastric hyperemic responses in a
concentration-dependent manner: a significant effect was observed at concentrations greater
than 1 mmol/l (Fig. 1B). The response of gastric mucosal blood flow to capsaicin (0.33, 1, and
3.3 mmol/l) during intragastric application for 10 min was 121.5 ± 2.6%, 146.4 ± 8.9%, and 178.6
± 12.9%, respectively. Interestingly, gastric mucosal blood flow in response to 3.3 mmol/l
capsaicin remained significantly high despite the removal of capsaicin from the chamber (Fig.
1A). At 20 and 50 minutes after removal of capsaicin, gastric mucosal blood flow showed a
persistent increase (about ~120–130%) as compared to pre-application values (Fig. 1C).
Mucosal application of the control solution (0.5% CMC) did not increase gastric mucosal blood
flow. Since the effect of capsaicin on gastric mucosal blood flow reached the maximum values
during the application and remained significantly elevated after removal of capsaicin at 3.3
mmol/l, this concentration was used in the following experiments for examining the effects of
various agents on the gastric mucosal blood flow in response to capsaicin.
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Figure 1. Effect of mucosal application of capsaicin on gastric mucosal blood flow (GMBF) in the ex vivo stomach of
anesthetized rats. Figure A shows the time course of analysis for GMBF in response to capsaicin (3.3 mmol/l) in anes‐
thetized rats. Capsaicin was topically applied to the mucosa for 10 min from time 0, and the stomach was perfused
with saline before and after the application. The data are expressed as a % increase of baseline values and represent
the means ± S.E. of values obtained every 2 or 10 min from 4 to 7 rats. * indicates statistically significant difference at
P<0.05 compared to the group treated with control (0.5% CMC). Figure B shows the maximum GMBF response during
capsaicin (0.33–3.3 mmol/l) application, and figure C shows the GMBF response at 20 and 50 min after removal of
capsaicin (0.33–3.3 mmol/l). The data are expressed as a % increase of baseline values, and represent the means ± S.E.
from 4 to 7 rats. * indicates statistically significant difference at P<0.05 compared to the group treated with control
(0.5% CMC). Note that GMBF in response to capsaicin (3.3 mmol/l) was significantly increased during application, and
remained moderately elevated even after removal of capsaicin from the chamber.
The increased gastric mucosal blood flow in animals in response to capsaicin (3.3 mmol/l) was
totally abolished in the animals when the mucosa was exposed to a TRPV1 antagonist BCTC
(0.8 mmol/l) (Fig. 2). The maximum response of gastric mucosal blood flow induced by 3.3
mmol/l capsaicin in the presence of BCTC was 102.4 ± 6.1% throughout the experiment. A
similar phenomenon was observed in the animals following chemical deafferentation by
consecutive injections of capsaicin (neurotoxic dose: total 100 mg/kg, s.c.) at two weeks before
the experiment (Fig. 2). In those animals, the gastric mucosal blood flow remained unchanged
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during and after exposure of the mucosa to capsaicin (3.3 mmol/l), the maximum response was
103.1 ± 4.2%. It was found that intragastric capsaicin produced a significant and persistent
increase in gastric mucosal blood flow via activation of TRPV1 expressed in capsaicin-sensitive
sensory nerves in anesthetized rats.
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Figure 2. Effects of BCTC, a TRPV1 antagonist, and sensory deafferentation on gastric mucosal blood flow (GMBF) in‐
duced by mucosal application of capsaicin in the ex vivo stomach of anesthetized rats. Figure A shows the time course
of analysis for GMBF response to capsaicin (3.3 mmol/l) in anesthetized rats treated with BCTC or sensory deafferenta‐
tion. Capsaicin was topically applied to the mucosa for 10 min and the stomach was perfused with saline before and
after the application. BCTC (0.8 mmol/l) was applied to the chamber for 30 min, starting at 20 min before the capsai‐
cin application. Chemical deafferentation (capsaicin pretreatment) was performed 2 weeks before the experiment by
consecutive injections of capsaicin s.c. once daily for 3 days (total dose: 100 mg/kg). The data are expressed as a %
increase of baseline values and represent the mean ± S.E. of values obtained every 2 or 10 min from 3 to 4 rats. * indi‐
cates statistically significant difference at P<0.05 compared to the group treated with vehicle. Figure B shows a maxi‐
mum response of GMBF induced by mucosal application of capsaicin (3.3 mmol/l). The data are expressed as a %
increase of baseline values and represent the mean ± S.E. from 3 to 4 rats. * indicates statistically significant difference
at P<0.05 compared to the group treated with vehicle. Note that increased GMBF in response to capsaicin was com‐
pletely abolished by BCTC and sensory deafferentation.
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3.2. Effects of L-NAME, a non-selective NOS inhibitor, and combined treatment with L-
arginine on gastric mucosal blood flow in response to capsaicin
Gastric mucosal blood flow was temporarily increased after the injection of L-NAME was
injected but immediately returned to the baseline value (Fig. 3A). The increase in gastric
mucosal blood flow in response to capsaicin (3.3 mmol/l) seen in control rats apparently
attenuated by L-NAME in a dose-dependent manner. The maximum response of gastric
mucosal blood flow in response to capsaicin in animals treated with L-NAME (5 and 10
mg/kg) was 138.8 ± 11.6% and 125.6 ± 11.6%, respectively (Fig.3B). The administration of 300
mg/kg L-arginine, a substrate for NOS, twice reversed the inhibitory effects of L-NAME (10
mg/kg) on gastric hyperemic response both during and after removal of capsaicin (Fig. 3).
Thus, gastric hyperemia in response to capsaicin was attributable to both NO-dependent
hyperemia during the application, followed by NO-dependent hyperemia alone after removal
of capsaicin in anesthetized rats.
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Figure 3. Effects of L-NAME, a non-selective NOS inhibitor, and combined treatment with L-arginine (300 mg/kg, x2)
on gastric mucosal blood flow (GMBF) induced by mucosal application of capsaicin in the ex vivo stomach of anesthe‐
tized rats. Figure A shows the time course of analysis for GMBF response to capsaicin (3.3 mmol/l) in anesthetized rats
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pretreated with L-NAMA and L-arginine. Capsaicin (3.3 mmol/l) was topically applied to the mucosa for 10 min and
the stomach was perfused with saline before and after the application. L-NAME (5 and 10 mg/kg) was given via intra‐
venous injection 20 min before capsaicin application. L-NAME by itself showed the temporary increase of GMBF when
was injected, but immediately returned to baseline value. L-arginine (300 mg/kg) was given via intravenous injection
40 and 60 min before capsaicin application. The data are expressed as a % increase of baseline values and represent
the means ± S.E. of values obtained every 2 or 10 min from 4 to 5 rats. * indicates statistically significant difference at
P<0.05 compared to the group treated with vehicle (saline). Figure B shows the maximum response of GMBF during
capsaicin (3.3 mmol/l) application in animals with L-NAME (5 and 10 mg/kg) or L-NAME (10 mg/kg) plus L-arginine
(300 mg/kg, x2). Figure C shows a response of GMBF at 20 and 50 min after removal of capsaicin (3.3 mmol/l) with L-
NAME (5 and 10 mg/kg) or L-NAME (10 mg/kg) plus L-arginine (300 mg/kg, x2). The data are expressed as a % in‐
crease of baseline values and represent the mean ± S.E. from 4 to 5 rats. * indicates statistically significant difference at
P<0.05 compared to the group treated with vehicle (saline). Note that increased GMBF during and after removal of
capsaicin was significantly inhibited by L-NAME (10 mg/kg), whose response was reversed by pretreatment with L-
arginine (300 mg/kg, x2).
3.3. Effect of NPLA, a selective nNOS inhibitor, on gastric mucosal blood flow in response
to capsaicin
The roles of different isoforms of NOS in the gastric hyperemia induced by capsaicin were
investigated by using selective NOS inhibitors including a nNOS inhibitor NPLA, an eNOS
inhibitor L-NIO, and an iNOS inhibitor 1400W. Administration of the nNOS-specific inhibitor
NPLA alone did not significantly affect gastric mucosal blood flow (Fig. 4A). Interestingly, the
increase in gastric mucosal blood flow in response to capsaicin (3.3 mmol/l) during the
application, but not after removal, was apparently decreased by 0.2 mg/kg NPLA. The
maximum responses of gastric mucosal blood flow during capsaicin application in animals
treated with NPLA (0.02 and 0.2 mg/kg) were 182.1 ± 26.6% and 141.9 ± 8.9%, respectively (Fig.
4B). In contrast, the persistent increase in gastric mucosal blood flow after removal of capsaicin
was not affected by NPLA (0.2 mg/kg), with the responses being 138.3 ± 17.3% and 126.5 ±
15.1%, respectively (Fig. 4C).
3.4. Effect of L-NIO, a selective eNOS inhibitor, on gastric mucosal blood flow in response
to capsaicin
Administration of the selective eNOS inhibitor L-NIO (10 mg/kg) by itself temporarily
increased gastric mucosal blood flow, but the gastric mucosal blood flow immediately returned
to the baseline value (Fig. 5A). The gastric hyperemic response after treatment with capsaicin
during the application was not significantly affected by L-NIO (3 and 10 mg/kg), and the
maximum responses being 158.7 ± 8.4% and 160.0 ± 9.6%, respectively (Fig. 5B). However, the
persistent increase in gastric mucosal blood flow after removal of capsaicin was obviously
attenuated by L-NIO (10 mg/kg) (Fig. 5A, C). In treatment with L-NIO (10 mg/kg), the gastric
mucosal blood flow responses at 20 and 50 min after removal of capsaicin were 96.2 ± 7.2%
and 89.5 ± 6.2%, respectively.
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Figure 4. Effect of NPLA, a selective neuronal NOS inhibitor, on gastric mucosal blood flow (GMBF) induced by capsai‐
cin in the ex vivo stomach of anesthetized rats. Figure A shows the time course of the effect of NPLA (0.2 mg/kg) on
GMBF response to capsaicin (3.3 mmol/l) in anesthetized rats. Capsaicin (3.3 mmol/l) was topically applied to the mu‐
cosa for 10 min and the stomach was perfused with saline before and after the application. NPLA (0.2 mg/kg) was
given via intravenous injection 20 min before capsaicin application. The data are expressed as a % increase of baseline
values and represent the means ± S.E. of values obtained every 2 or 10 min from 4 rats. * indicates statistically signifi‐
cant difference at P<0.05 compared to the group treated with vehicle (saline). Figure B shows the maximum response
of GMBF response during capsaicin (3.3 mmol/l) application in animals with NPLA (0.02 and 0.2 mg/kg). Figure C
shows a response of GMBF at 20 and 50 min after removal of capsaicin (3.3 mmol/l) with NPLA (0.02 and 0.2 mg/kg).
The data are expressed as a % increase of baseline values and represent the means ± SE from 4 to 5 rats. * indicates
statistically significant difference at P<0.05 compared to the group treated with vehicle (saline). Note that increased
GMBF during capsaicin application was inhibited by NPLA, yet persistent increase in GMBF after removal of capsaicin
was not affected by NPLA.
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Figure 5. Effect of L-NIO, a selective endothelial NOS inhibitor, on gastric mucosal blood flow (GMBF) induced by cap‐
saicin in the ex vivo stomach of anesthetized rats. Figure A shows the time course of analysis for the effect of L-NIO (10
mg/kg) on GMBF response to capsaicin (3.3 mmol/l) in anesthetized rats. Capsaicin (3.3 mmol/l) was applied topically
to the mucosa for 10 min and the stomach was perfused with saline before and after the application. L-NIO (10
mg/kg) was injected intravenously 20 min before capsaicin application. L-NIO by itself induced a temporary increase
of GMBF when injected, but it immediately returned to baseline value. The data are expressed as a % increase of base‐
line values and represent the means ± S.E. of values obtained every 2 or 10 min from 4 rats. * indicates statistically
significant difference at P<0.05 compared to the group treated with vehicle (saline). Figure B shows the maximum re‐
sponse of GMBF response during capsaicin (3.3 mmol/l) application in animals with L-NIO (3 and 10 mg/kg). Figure C
shows the response of GMBF at 20 and 50 min after removal of capsaicin (3.3 mmol/l) with L-NIO (3 and 10 mg/kg).
The data are expressed as a % increase of baseline values and represent the means ± S.E. from 4–5 rats. * indicates
statistically significant difference at P<0.05 compared to the group treated with the vehicle (saline). Note that L-NIO
significantly inhibited persistent increase of GMBF after removal of capsaicin, although GMBF response during capsai‐
cin application was not affected by L-NIO.
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3.5. Effect of 1400W, a selective iNOS inhibitor, on gastric mucosal blood flow in response
to capsaicin
Gastric mucosal blood flow remained unchanged by the administration of an iNOS selective
inhibitor 1400W (10 mg/kg) (Fig. 6). In addition, the increased gastric mucosal blood flow I
response to capsaicin was not also affected by 1400W (3 and 10 mg/kg) (Fig. 6).
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Figure 6. Effect of 1400W, a selective inducible NOS inhibitor, on gastric mucosal blood flow (GMBF) induced by cap‐
saicin in the ex vivo stomach of anesthetized rats. Figure A shows the time course of analysis for the effect of 1400W
(10 mg/kg) on GMBF response to capsaicin (3.3 mmol/l) in anesthetized rats. Capsaicin (3.3 mmol/l) was topically ap‐
plied to the mucosa for 10 min and the stomach was perfused with saline before and after the application. 1400W (3
and 10 mg/kg) was given via intravenous injection 20 min before capsaicin application. The data are expressed as a %
increase of baseline values and represent the means ± S.E. of values obtained every 2 or 10 min from 4 rats. Figure B
shows the maximum response of GMBF response during capsaicin (3.3 mmol/l) application in animals treated with
1400W (3 and 10 mg/kg). Figure C shows the responses of GMBF (3.3 mmol/l) at 20 and 50 min after removal of cap‐
saicin. The data are expressed as a % increase of baseline values and represent the mean ± S.E. from 4 to 5 rats. Note
that increased GMBF in response to capsaicin was not affected by 1400W.
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside114
3.6. TRPV1-immunoreactivity in corpus and antrum of stomach
Extensive TRPV1-immunoreactivity was detected in fundus, corpus and antrum of the
stomach [4, 19]. Immunoreactivity was present in all layers of the corpus and in all cases
appeared axon-like in nature (Fig. 7A). This identification was confirmed by double labeling
with the pan axonal marker PGP 9.5, which confirmed that all TRPV1 immunoreactive
structures were also PGP 9.5 immunoreactive (Figure 7C). However, not all PGP 9.5-immu‐
noreactive fibers were TRPV1-immunoreactive, reflecting the fact that only a subpopulation
of neural elements in the stomach expresses TRPV1. TRPV1 immunoreactivity was also not
seen in the PGP 9.5 immunoreactive cell bodies of the myenteric plexus or submucosal plexus.
In control experiments, TRPV1-immunoreactivity was not observed in any corpus sections
processed without the primary antibody. Similar observation was obtained in all layers of
antrum of the stomach [4].
cm
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* *
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Figure 7. Distribution of TRPV1-immunoreactivity in corpus of rat stomach. mu: mucosa; su: submucosa; cm: circular
muscle. (A) A low magnification image showing that TRPV1-immunoractivity is present in all layers of corpus. Asterisk
indicates a blood vessel. (B) A high magnification image showing that TRPV1-immunoractivity is present in submucos‐
al and muscular layers of corpus. TRPV1-immunoreactive fibers are observed associated with small blood vessels (as‐
terisk) or along and in the lamina muscularis mucosae. Numerous TRPV1-immunoreactive fibers are found around
blood vessels (asterisks) in the submucosal layer. TRPV1-immunoreactive axons are sparse in longitudinal smooth mus‐
cle but isolated varicose fibers are present. Fibers are abundant in circular muscle layer where they run parallel to mus‐
cle fibers. A large number of nerve fibers are seen in circular smooth muscle layer and in the myenteric nerve plexus.
(C) Co-localization of TRPV1-positive neurons with protein gene product 9.5 (PGP 9.5) in corpus submucosa. Rat stom‐
ach sections were dual-labelled with TRPV1 in green and PGP 9.5 in red. Merged image is shown in (C). Arrows indi‐
cate the co-localization of TRPV1 immunoreactivity with PGP 9.5 immunoreactivity. All TRPV1 immunoreactive
structures are PGP 9.5 immunoreactive. Note that in circular smooth muscle, the TRPV1 immunoreactive axons repre‐
sent a relatively small population of the total population of PGP 9.5 immunoreactive axons. Scale bars are 100 µm in
(A) and 50 µm in (B), (C).
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The TRPV1-immunoreactive varicose fibers were present in the mucosa along gastric glands
of corpus and antrum, although Ward et al. (2003) did not observe TRPV1 immunoreactive
fibers that penetrate the mucosa [20]. A few TRPV1-immunoreactive varicose nerve fibers were
observed in the lamina propria, mainly in association with small vessels or along the muscu‐
laris mucosae of antrum and corpus [4, 19]. Numerous TRPV1-immunoreactive axons were
also found around arterioles in the submucosal layer. A dense TRPV1-innervation of the
submucosal blood vessels was seen running along the major arterioles (Fig. 7B). Occasionally
fibers formed baskets around the vessels [4].
3.7. Coexistence of TRPV1 and nNOS
Many TRPV1 axons were also observed to be immunoreactive for nNOS (Figure 8). A few
axons of this type were present in the mucosa and smooth muscle layers but were particularly
abundant in the vicinity of blood vessels in the submucosa [21]. Numerous TRPV1-immunor‐
eactive axons were found around arterioles in the mucosal and submucosal layer.
A
B
C
Figure 8. Confocal images showing co-localization of TRPV1-and neuronal NOS-immnuoreactivities in corpus submu‐
cosa and muscle. Labeling for TRPV1 (A: green) and neuronal NOS (B: red) is shown separately, and merged in (C).
Double immunolabeling for TRPV1 and neuronal NOS demonstrated co-localization in many but not all axons. This
photo shows abundant TRPV1 axons containing neuronal NOS in the submucosa, with a high density of immounor‐
eactive axons around blood vessels (asterisk). mu: mucosa; sm: submucosa; cm: circular muscle. Scale bars is 100 µm.
4. Discussion
This report showed that intragastric application of capsaicin facilitates an initial increase in
gastric mucosal blood flow by NO mainly derived from nNOS after stimulating capsaicin-
sensitive sensory nerves, and also the persistent increase in gastric mucosal blood flow after
removal of capsaicin is attributed to eNOS/NO in the rat stomach.
Topical application of capsaicin causes dilatation of the submucosal and mucosal arterioles in
the rat stomach [22, 23], but it has not been fully elucidated how capsaicin really activates
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primary afferent vasodilator neurons in the stomach. Primary afferent neurons express TRPV
1 channels, which mediates the gastrointestinal vasodilator effect of capsaicin. By the use of
the TRPV1 blocker BCTC, it was found that this TRPV1 channels appear to participate in the
capsaicin-induced hyperemia in the rat stomach [21]. Nerve-selective ablation of capsaicin-
sensitive afferent neurons has revealed that the mucosal hyperemic response to local capsaicin
administration in the rat stomach is mediated by primary afferent vasodilator neurons that
originate in the dorsal root ganglia. It was inferred that the capsaicin-induced increase of blood
flow is relayed entirely by a peripheral reflex circuit via the TRPV1 activation. The gastric
hyperemic response to capsaicin results from an axon reflex between mucosal and submucosal
collaterals of afferent neurons [24]. Evidence for an axon reflex-type innervation has been
found in submucosal arterioles of the guinea pig ileum in which focal application of capsaicin
evokes vasodilatation that spreads beyond the application site [25].
It is known that NO, the endothelium-derived vasodilator, plays an important role in the
regulation of the resting gastric mucosal microcirculation [26, 27]. Indeed, an increase in both
systemic arterial blood pressure and gastric mucosal blood flow was observed under physio‐
logical conditions in rats after a bolus administration of L-NAME.
The gastric mucosal blood flow responses to capsaicin were markedly inhibited by a non-
selective NOS inhibitor L-NAME, which indicated that NO is mainly involved in those
hyperemic responses. However, L-NAME did not completely inhibit the increases in gastric
mucosal blood flow as much as BCTC. This result suggests that gastric mucosal hyperemia in
response to capsaicin is attributable not only to NO but also to other mediators including CGRP
and prostaglandins (PGs). Several studies have shown that endogenous PGs, contributes to
gastric hyperemic responses to capsaicin by sensitizing TRPV1-expressing afferent nerves,
which was revealed by the treatment of indomethacin (5 mg/kg, s.c.) and the animals lacking
IP receptors [28]. In addition, Chen et al. reported the interaction of NO and CGRP in gastric
vasodilation through sensory nerves [14]. Our results can be explained on the basis of the
previous findings that BCTC functionally antagonizes the action of capsaicin at the peripheral
terminals of sensory nerves and inhibits the release of some transmitters such as CGRP and
NO from capsaicin-sensitive afferent nerves. Further, the submucosal application of CGRP
induced dose-dependent dilation of gastric submucosal arterioles, which was significantly
decreased by L-NAME [23]. However, the dilation induced by submucosal CGRP was
decreased to a much lesser degree by inhibition of NO synthesis than that induced with
intragastric capsaicin [14]. This indicates that NO released by CGRP is not the only source of
submucosal NO in capsaicin-induced vasodilation, and there may be other source of submu‐
cosal NO, such as from nitroxidergic nerves that has not been determined thus far [29]. The
existence of capsaicin-sensitive nitroxidergic nerves is hypothesized by some reports, but it
was not proved [6].
NO is synthesized from L-arginine by NOS in various cells. NOS is present not only in vascular
endothelial cells (eNOS) but also in perivascular nerves (nNOS) [10, 30]. It is well known that
NO is a vasodilator that increases gastric mucosal blood flow, and this gas mediator is
important in the modulation of gastric mucosal integrity through interaction with sensory
nerves [6]. The increase in gastric mucosal blood flow responses to capsaicin is mitigated by
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NG-monomethyl L-arginine, and the gastroprotection induced by capsaicin is also decreased
by the NOS inhibitor [8, 31]. Previous studies have shown that gastric hyperemia caused by
acid back-diffusion or exogenous CGRP is mediated partly by NO, but which NOS isoform is
involved in those hyperemic responses has not been investigated in any of the studies thus far.
In addition, the source of NO involved in the actions of capsaicin was not identified [29]. That
is because highly selective inhibitors for NOS isoforms had not been developed at that time.
We investigated which NOS isoform mediates the increased gastric mucosal blood flow in
response to capsaicin by using newly developed NOS inhibitors.
In this study, NPLA and L-NIO were adopted as selective nNOS and eNOS inhibitors,
respectively. It was reported that the potency of inhibition for nNOS by NPLA is 3158 times
that for iNOS and 149-fold that for eNOS, whose selectivity for nNOS/iNOS and nNOS/eNOS
are ratio of the inverse of IC50 values [32, 33]. L-NIO and 1400W were also reported to be as
selective inhibitors for eNOS and iNOS, respectively [34, 35].
Intravenous injection of L-NIO alone of L-NAME alone produced a temporary increase in
gastric mucosal blood flow, although intravenous injection of NPLA did not affect the gastric
mucosal blood flow. Therefore, eNOS-derived NO homeostatically regulates gastric mucosal
blood flow under physiological conditions. In the increased gastric mucosal blood flow in
responses to capsaicin, NPLA significantly decreased the maximum response of gastric
mucosal blood flow during the application of capsaicin, but NPLA did not affect the increase
in gastric mucosal blood flow after removal of capsaicin. In contrast, L-NIO significantly
decreased gastric mucosal blood flow responses after removal of capsaicin, but did not affect
the maximum response of gastric mucosal blood flow induced by capsaicin during the
application. These results suggested that nNOS/NO, which may be released from TRPV1-
expressing nerves stimulated by capsaicin, plays an important role in gastric hyperemia during
the luminal application of capsaicin (as in the early phase). eNOS/NO plays a role in regulating
gastric mucosal blood flow responses after removal of capsaicin (as in the late phase). On the
other hand, intravenous injection of 1400W did not affect the baseline value of gastric mucosal
blood flow as well as the increase in gastric mucosal blood flow in response to capsaicin.
Our results were consistent with those reported previously that eNOS was expressed mostly
in the vasculature throughout the gastric mucosa in rats, but the expression of iNOS was hardly
observed in the gastric mucosa of normal rats by using immunohistochemical analysis [11,
12]. These findings support our hypothesis that eNOS/NO plays a role in the resting state
responses of gastric mucosal blood flow in the late phase, while iNOS/NO plays no role in the
increased GMBF in response to capsaicin.
In our immunohistochemical studies, TRPV1 immunoreactivity was detected in mucosal and
submucosal layers of the corpus of the rat stomach. Many TRPV1 nerve fibers contain nNOS,
but not all axons do. In addition, numerous TRPV1-immunoreactive axons were also found
around arterioles in the submucosal layer. These data led us to speculate that the capsaicin-
induced increase in gastric mucosal blood flow could be attributed to the time-dependent
interaction of both nNOS/NO and eNOS/NO. Namely, it is suggested that capsaicin stimulates
TRPV1 nerves and releases CGRP and NO from the sensory nerve endings. The NO is
immediately provided by nNOS and dilates the blood vessels in the early phase. On the other
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hand, NO derived from eNOS, but not nNOS, maintains the persistent dilation of the blood
vessels after capsaicin application in rat stomachs (in the late phase) (Fig. 9).
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Figure 9. Putative mechanism underlying increase of gastric mucosal blood flow due to activation of TRPV1 channels.
Capsaicin increases blood flow in the rat stomach by a peripheral axon reflex-like circuit. Capsaicin excites primary af‐
ferent neurons that originate in the dorsal root ganglia and that arborize into several branches that innervate mucosa
and submucosal arterioles. The reflex hyperemia is mediated by calcitonin gene-related peptide (CGRP) and nitric ox‐
ide (NO) that form most likely in the endothelium. The involvement of NO derived from nNOS in hyperemia is newly
clarified. The primary afferent neurons release NO/nNOS to dilate blood vessels.
Stimulation of sensory nerves leads to gastric hyperemic response, which is mediated partly
by NO formation, but it is not clear whether the NO is derived solely from endothelial cells or
is also released directly by extrinsic and/or intrinsic nerves [6, 14]. We have reported that
abundant TRPV1 axons containing nNOS in the submucosa with a high density of immunor‐
eactive axons around blood vessels [21]. Therefore, our study suggests that capsaicin is likely
to induce vasodilatation by inducing NO release from TRPV1-expressing sensory fibers.
5. Conclusion
The mucosal application of capsaicin increased gastric mucosal blood flow by releasing NO
derived from nNOS after stimulating capsaicin-sensitive sensory nerves. The contribution of
nNOS-derived NO in gastric hyperemic responses to the activation of TRPV1 by capsaicin has
been reported using not only pharmacological but also immunohistochemical techniques. We
also demonstrated the interaction between nNOS/NO and eNOS/NO on the increased gastric
mucosal blood flow by capsaicin in time-dependently, whose hyperemic responses were
composed of the both nNOS/NO in the early phase and eNOS/NO in the late phase.
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Terminology
1400W: a selective inducible NOS inhibitor
ANOVA: analysis of variance
BCTC: N-(4-t-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide:
a TRPV1 antagonist
CGRP: calcitonin gene-related peptide
GMBF: gastric mucosal blood flow
iNOS: inducible NO synthase
eNOS: endothelial NO synthase
L-NIO: N5-(l-iminoethyl)-L-ornithine: a selective endothelial NOS inhibitor
nNOS: neuronal NO synthase
NO: nitric oxide
NPLA: N5-[imino (propylamino) methyl]-L-ornithine: a selective nNOS inhibitor
TRPV1: transient receptor potential vanilloid type 1
S.E.M.: standard error of mean
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